Purine Nucleoside Analogs in Indolent Non-Hodgkin’s Lymphoma
June 27th 2000This article details both the contribution of the purine nucleoside analogs to the current management of relapsed indolent non-Hodgkin’s lymphoma (NHL) and the role of pentostatin (Nipent) in that management. Of the three
Magnetic Resonance Imaging of the Abdomen: Applications in the Oncology Patient
June 27th 2000Cross-sectional imaging of the abdomen in oncology patients presents unique challenges and opportunities. A close working relationship between the oncologist and radiologist is essential for the exchange of the clinical and
Common p53 Gene Test Helps Predict Cancer Recurrence in Mastectomy Patients
June 1st 2000A common blood protein test can predict which breast cancer patients are at risk for recurrence after mastectomy. The test may eventually help direct treatment decisions, speculate researchers from the University of Texas Health Sciences Center at
Promising Results With Targeted Drug Delivery System for Primary Liver Cancer
June 1st 2000FeRx Incorporated, a privately held development stage drug delivery company, recently reported encouraging data from its phase I/II clinical trial of doxorubicin adsorbed to magnetic targeted carriers (MTC-DOX), for the treatment of patients with
Breath Test Identifies Patients Who Should Get Lower Chemotherapy Doses
June 1st 2000A relatively simple technique, pioneered by a North Carolina physician, can distinguish between patients who can metabolize docetaxel (Taxotere) normally and those who need to receive lower doses for safety, according to a recent study. Researchers
ADA Inhibitors: Recent Developments and Future Directions in Low-Grade Lymphoma
June 1st 2000Pentostatin (Nipent) is a nucleoside analog that inhibits the activity of the enzyme adenosine deaminase. Inhibition of adenosine deaminase blocks the deamination of adenosine to inosine and deoxyadenosine to deoxyinosine in the purine
3D CRT More Cost-Effective Than Conventional RT for Prostate Cancer
June 1st 2000Three-dimensional conformal radiation therapy (3D CRT) is more effective yet costs no more than conventional radiation therapy in the long-term treatment of prostate cancer, according to a study conducted at Fox Chase Cancer Center in
Economic Consequences of Cancer Treatment–Related Fatigue
June 1st 2000Cancer treatment–related fatigue, the most prevalent and debilitating side effect of chemotherapy, has a significant impact on the economic well-being of patients and their caregivers, according to a national survey of more than 300 cancer patients. The
Research Challenges Conventional Thinking About Prostate Cancer Treatment
June 1st 2000Physicians have long known that male hormones fuel prostate cancer growth. That’s why therapies that block the production of androgen-or testosterone-provide some of the most effective therapies for advanced prostate cancer. Certain drugs, for
Study Finds Estrogen May Fuel Lung Cancer Growth
June 1st 2000Long known to be instrumental in fueling the growth of breast cancer, estrogen may spur the same process in lung cancer, according to the findings of a University of Pittsburgh study presented at the annual meeting of the American Association for
Magnetic Resonance Imaging for Intra-abdominal Malignancy
June 1st 2000Accurate imaging of the hepatic and extrahepatic abdomen is an important component of the management of many patients with cancer. Historically, clinicians have relied on computed tomography (CT). The use of intravenous (IV) and oral contrast
Cell Phone Users May Still Be At Risk for Brain Cancer
June 1st 2000With worldwide use of cellular phones rising exponentially, a team of Swedish medical investigators is raising renewed concerns about the link between brain tumors and cell phones in a new, peer-reviewed article posted on the Medscape
AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends
June 1st 2000In his excellent review, Dr. Mitsuyasu correctly highlights the three most important ingredients that play a role in the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma (KS)-Kaposi’s sarcoma herpesvirus/human herpesvirus type 8 (KSHV/HHV-8); altered expression and response to cytokines; and stimulation of KS growth by the human immunodeficiency virus (HIV)-1 trans-activating protein, Tat. Recent studies have provided tremendous insight into the process whereby KSHV/HHV-8 creates the inflammatory-angiogenic state that characterizes KS.
Commentary (Shah): Current Status of Voice Restoration Following Total Laryngectomy
June 1st 2000Drs. Mark Singer and Eric Blom revolutionized the process of speech rehabilitation following total laryngectomy with their introduction of the tracheoesophageal puncture and insertion of a duck bill prosthesis.[1-5] The physiologic principles of the procedure are obvious, the surgical technique is simple, and the results in terms of fluent speech production are immediate and quite satisfactory. Dr. Blom is to be complimented for providing in this article, a succinct summary of the “current methods” available for speech rehabilitation for a patient facing total laryngectomy.
Oral Therapy for Colorectal Cancer: How to Choose
June 1st 2000Heidelberger and associates[1] synthesized fluorouracil (5-FU) in 1957 after observing that rat hepatomas utilized radiolabeled uracil more avidly than malignant tissues. For the past 40 years, 5-FU has been extensively investigated in various schedules, in combination with biochemical modulators, and for a variety of malignancies.[2]
AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends
June 1st 2000Dr. Mitsuyasu has been doing clinical research in patients with AIDS-related Kaposi’s sarcoma (KS) since the beginning of the AIDS epidemic, and his review reflects this breadth of experience. It provides a well-rounded and up-to-date assessment of the pathophysiology, evaluation, and treatment of AIDS-related KS that should be a useful guide for practicing physicians.
AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends
June 1st 2000In his article, Dr. Mitsuyasu concisely reviews a large body of data concerning the etiology, pathogenesis, epidemiology, and treatment of Kaposi’s sarcoma (KS) in the setting of the human immunodeficiency virus (HIV) infection. As he correctly points out, effective highly active antiretroviral therapy (HAART), with its consequent improvements in immune function and decrease in production of viral and cytokine cofactors that promote KS growth, has been partly responsible for the decline of KS incidence in areas with ready access to HIV therapy.
Oral Therapy for Colorectal Cancer: How to Choose
June 1st 2000Damjanov and Meropol review the status of several oral fluoropyrimidine drugs that are currently undergoing clinical testing for the treatment of colorectal cancer. Meta-analysis indicates an 8% improvement in the overall response rate and a survival advantage of 0.8 months with infusional vs bolus fluorouracil (5-FU)-arguably small differences. The incidence of grade 3-4 diarrhea, mucositis, and myelosuppression is < 10% with infusional 5-FU, although hand-foot syndrome is commonly associated with this therapy. The prevailing strategy for the development of oral 5-FU drugs employs multiple daily dosing for periods of 2 to 4 weeks followed by a 1- or 2-week break in order to mimic the protracted infusional schedule.UFT
Current Status of Voice Restoration Following Total Laryngectomy
June 1st 2000Total laryngectomy is the surgical procedure traditionally used to treat patients with advanced-stage cancer of the larynx. The impairments resulting from removal of such a small organ are, indeed, profound. They include
Infectious Complications of Pentostatin Therapy
Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited
Pentostatin and Rituximab in the Treatment of Patients With B-Cell Malignancies
June 1st 2000Both pentostatin (Nipent) and rituximab (Rituxan) have single-agent activity in B-cell malignancies, including indolent and intermediate-grade non-Hodgkin’s lymphoma (NHL). Pentostatin is also active in pretreated patients